Benzinga | Feb 18, 2021 11:52AM EST

Cowen & Co. Maintains Outperform on BeiGene, Raises Price Target to $429

Cowen & Co. analyst Yaron Werber maintains BeiGene (NASDAQ:BGNE) with a Outperform and raises the price target from $348 to $429.